Overview

Dysport for the Treatment of OMD

Status:
Completed
Trial end date:
2017-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
Ipsen
Treatments:
abobotulinumtoxinA
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA